Boehringer to get Zantac rights as part of J&J-Pfizer deal

10/12/2006 | Yahoo!

Johnson & Johnson and Pfizer say they will sell U.S. marketing rights for the heartburn drug Zantac to Boehringer Ingelheim Pharmaceuticals for $509.5 million as part of J&J's planned acquisition of Pfizer's consumer health business. The sale is intended to facilitate Federal Trade Commission approval of the $16.6 billion J&J-Pfizer deal.

View Full Article in:

Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY